Nanjing Gaoke Co

Nanjing Gaoke Co Gross Margin

The Gross Margin of Nanjing Gaoke Co (600064.SS) as of Nov 2, 2026 is 23.17 %. In the previous year, Gross Margin was -17.06 % — a change of -235.80% (higher).

Gross Margin

23.17 %

YoY

-235.80%

Last updated:

Gross Margin of Nanjing Gaoke Co is 2025 23.17 % . Gross Margin of Nanjing Gaoke Co was 2024 -17.06 % . It decreases by -235.80% higher compared to the previous year.

Nanjing Gaoke Co's gross margin stands at 23.2%, broadly stable from 23.0% several years earlier.

The Nanjing Gaoke Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
49.30 CNY
Jan 1, 2019
29.79 CNY
Jan 1, 2020
39.45 CNY
Jan 1, 2021
23.00 CNY
Jan 1, 2022
18.63 CNY
Jan 1, 2023
-0.43 CNY
Jan 1, 2024
-17.06 CNY
Jan 1, 2025
23.17 CNY
The Nanjing Gaoke Co Gross Margin history
YEARGross MarginYoY
23.17 %-235.80%
-17.06 %+3,903.70%
-0.43 %-102.29%
18.63 %-19.01%
23.00 %-41.71%
39.45 %+32.44%
29.79 %-39.58%
49.30 %+11.96%
44.04 %+18.92%
37.03 %+23.98%
29.87 %-10.15%
33.24 %+12,000.96%
0.27 %-35.63%
0.43 %+9.67%
0.39 %+34.52%
0.29 %+22.86%
0.24 %-13.87%
0.27 %+19.13%
0.23 %+25.39%
0.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nanjing Gaoke Co Stock analysis

What does Nanjing Gaoke Co do? Nanjing Gaoke Co., Ltd. generates revenue through its property and municipal business, pharmaceutical operations, and equity investment activities. The company develops residential and commercial properties, manages real estate assets, and provides municipal services in Nanjing, Jiangsu province. Its pharmaceutical business focuses on research, manufacturing, and selling drugs, while equity investments contribute to its income stream. The primary customers for real estate are residents and businesses seeking residential or commercial spaces, and pharmaceutical buyers include healthcare providers and patients in the local market. The company's property and municipal business serves local communities and businesses in Nanjing, Jiangsu, with residential development and property management as key revenue drivers. Pharmaceutical sales target healthcare institutions and end-users within Jiangsu province, leveraging the firm's R&D capabilities. Equity investment activities support diversified income generation without specifying external partners or markets. Nanjing Gaoke's real estate segment includes residential and commercial projects, while its pharmaceutical division handles drug production and distribution. The firm's municipal services integrate with property management to enhance community offerings. Equity investments provide additional financial returns, though specific investment targets are not detailed in the description. Nanjing Gaoke Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nanjing Gaoke Co stock

Gross Margin of Nanjing Gaoke Co is 23.17 % in 2025.

Gross Margin of Nanjing Gaoke Co changed from -17.06 % to 23.17 %, representing a -235.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Nanjing Gaoke Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Nanjing Gaoke Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Nanjing Gaoke Co

All Key Metrics — Nanjing Gaoke Co